Intratumoral Bleomycin and IL-12 Electrochemogenetherapy for Treating Head and Neck Tumors in Dogs

Abstract

Bleomycin and Interleukin 12 have been used clinically to treat tumors; however, the co-administration of Bleomycin and Interleukin 12 followed by electroporation has not been tested clinically. In this study, dogs with spontaneous head and neck tumors were treated with one co-administration of Bleomycin and Interleukin 12 plasmid DNA followed by electroporation. The regression of the recurrent papillary tumor and the adjacent metastatic bone tumor was analyzed by multiple CT scans. The papillary tumor was completely eradicated in less than 2 weeks, and the bone tumor was not visible 23 weeks after the administration.

Intramuscular IL-12 Electrogene Therapy for Treatment of Spontaneous Canine Tumors

“…In clinical settings, intratumoral IL-12 EGT has been successfully used both in humans (Daud et al, 2008), as well as dogs (Cutrera et al, 2008;Pavlin et al, 2011;Reed et al, 2010). In all of presently published studies in tumor-bearing dogs, EGT has been performed with intratumoral delivery of IL-12 either alone (Chuang et al, 2009;Pavlin et al, 2011), or in combination with electrochemotherapy with bleomycin (Cutrera et al, 2008;Reed et al, 2010). The only published intramuscular IL-12 EGT in dogs was performed on healthy experimental beagles (Pavlin et al, 2008), showing feasibility, efficacy and safety of this approach.…”

Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions

“…Anesthesia was induced with intravenous propofol and maintained on isoflurane in oxygen. The pDNA was diluted in half-strength saline to the proper concentration The details of the anesthesia and other general veterinary practices were performed as per standard operating procedures as previously described [20]. Once the subject was fully anesthetized, the tumor was measured via calipers or a small millimeter ruler, as necessary for tumors in the oral cavity of small breed canines.…”

Immunotherapy in Veterinary Oncology

“…Many have investigated the in vitro and/or in vivo effects of the soluble cytokine (eg, interferons, IL-2, IL-12, and IL-15) [38][39][40][41][42][43][44][45][46][47][48][49] or liposome encapsulation of the cytokine (eg, liposomal IL-2) 39,50-53 or use a virus, cell, liposome-DNA complex, plasmid, or other mechanism to expresses the cytokine (eg, recombinant poxvirus expressing IL-2). 50,54-61 The European Committee for Medicinal Products for Veterinary Use adopted a positive opinion in March 2013 for the veterinary product, Oncept IL-2 (feline poxvirus expressing recombinant feline IL-2).…”